EIF2AK3 and metabolic syndrome: Similar to the presented effect on human ASCs cells, calystegines have also been previously demonstrated to reduce aberrant ER stress in equine ASCs cells effected by metabolic syndrome via the regulation of PERK, BiP, CHOP and eI2F-α transcripts [23].